Pasithea Therapeutics Appoints Experienced CMO, Grants Substantial Equity Options to Executives and Directors
KTTA has more than doubled off its 52-week low of $0.281.
Summary
Pasithea Therapeutics appointed Dr. Kartik Krishnan as Chief Medical Officer, a strategic move for its clinical-stage pipeline, accompanied by significant stock option grants to executives and directors.
Key Events · Executive and Board Changes · KTTA
-
Chief Medical Officer Appointed
Dr. Kartik Krishnan, M.D., Ph.D., was appointed Chief Medical Officer, effective May 1, 2026. He will oversee clinical development and medical strategy for PAS-004, particularly for neurofibromatosis type 1 (NF1).
-
Extensive Industry Experience
Dr. Krishnan has over 20 years of experience, including roles as CEO at OncoNano Medicines and CMO at Arcus Biosciences. His prior work at Genentech on the FDA-approved MEK inhibitor cobimetinib is directly relevant to Pasithea's lead candidate.
-
Executive Compensation Details
Dr. Krishnan's employment agreement includes an initial annual base salary of $500,000 and eligibility for an annual discretionary bonus of up to 40% of his base salary.
-
Significant Stock Option Grants
The Board approved stock option awards for 5,865,170 shares of common stock to executive officers (including Dr. Krishnan, CEO Tiago Reis Marques, and Daniel Schneiderman), certain employees, and non-employee directors. The exercise price for all options is $0.841 per share, the closing price on May 1, 2026.
Analysis · KTTA · Life Sciences
Pasithea Therapeutics, a clinical-stage biotechnology company, has appointed Dr. Kartik Krishnan as its Chief Medical Officer. Dr. Krishnan brings over 20 years of experience in clinical development, including work on an FDA-approved MEK inhibitor, which is highly relevant to Pasithea's lead candidate, PAS-004, for neurofibromatosis type 1 (NF1). This appointment is a significant positive for the company's clinical strategy and its ability to advance PAS-004. In connection with this, the company granted substantial stock options to Dr. Krishnan, the CEO, CFO, other employees, and non-employee directors. While these grants represent significant potential future dilution, they are a necessary component of attracting and retaining key talent critical for a clinical-stage biotech's success.
At the time of this filing, KTTA was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.1M. The 52-week trading range was $0.28 to $3.79. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.